Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "DNA cross-linking agent binding site on DNA strands" refers not to a single molecule but rather the specific loci within double-stranded genomic DNA where certain chemotherapeutic agents covalently bind. These sites are typically nitrogen atoms or oxygen atoms within nucleobases—most commonly guanine's N7 position—and occasionally adenine or cytosine residues. The covalent attachment forms either interstrand or intrastrand bridges between bases that physically prevent the normal unwinding and separation of the two complementary strands required for essential cellular processes such as replication and transcription. This blockade leads ultimately to replication fork stalling, activation of cell cycle checkpoints, apoptosis induction if damage persists unrepaired. Crosslink formation can also involve proteins bound near these sites resulting in bulky lesions called DNA-protein crosslinks which further complicate genome maintenance. Agents that induce these lesions include nitrogen mustards, platinum-based drugs like cisplatin, mitomycin C, psoralens among others—all widely used anticancer drugs exploiting this mechanism selectively against rapidly proliferating tumor cells. The efficacy depends heavily upon cellular capacity for lesion recognition and removal through complex repair pathways involving nucleotide excision repair enzymes and homologous recombination factors. In summary, this "target" represents critical chemical interaction points exploited pharmacologically rather than classical biological macromolecules like receptors or enzymes[1][2][3][4].
Drugs bind covalently to nucleotides at defined positions such as guanine N7, adenine N1/N3/N7, cytosine N3, thymidine O4 forming: - Interstrand crosslinks that link complementary strands preventing strand separation. - Intrastrand crosslinks within one strand causing helix distortion. - Crosslinks between proteins and DNA blocking enzymatic processes. This prevents unwinding necessary for replication/transcription leading to cell death if unrepaired.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA cross-linking agent binding site on DNA strands.